Biocon Biologics  /  News  /  Media Stories

MEDIA STORIES

Biocon included in S&P Global Sustainability Yearbook 2024

 20-Feb-2024

external_link-01
Biocon Biologics focusing on market share gains of biosimilars in key markets

 13-Feb-2024

external_link-01
We are focused on consolidating our acquired businesses for the coming fiscal year: Biocon Biologics

 12-Feb-2024

external_link-01
Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia

 09-Feb-2024

external_link-01
Budget ’24 | A vision of ‘Viksit Bharat’, driven by inclusion and innovation: Kiran Mazumdar Shaw

 02-Feb-2024

external_link-01
Biocon to commercialize biosimilars in 31 European countries

 22-Dec-2023

external_link-01
Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan

 22-Dec-2023

external_link-01
Biocon Biologics completes integration of Viatris’ biosimilars business

 18-Dec-2023

external_link-01
Biocon Biologics Clinches Seventh Consecutive Asia IP Elite Recognition

 15-Dec-2023

external_link-01
Biocon Biologics integrates Viatris’ biosimilar biz in 31 European nations

 30-Nov-2023

external_link-01
Interview With Shreehas Tambe, MD On Biocon’s Strong Q2 Earnings And Acquisition Plans

 15-Nov-2023

external_link-01
Biocon Biologics targets top three biosimilar spot: Shreehas Tambe

 13-Nov-2023

external_link-01
Biocon Biologics receives UK regulator’s approval for ophthalmic drug YESAFILI

 13-Nov-2023

external_link-01
Biocon Biologics to sell 2 non-core branded formulations businesses to Eris Lifesciences for ₹366 cr

 08-Nov-2023

external_link-01
Kedar Upadhye steps in as new CFO of Biocon Biologics

 19-Oct-2023

external_link-01
Biocon Biologics integrates Viatris Biosimilars in North America, shares up

 07-Sep-2023

external_link-01
Biocon Biologics announces top leadership appointments

 04-Aug-2023

external_link-01
Biocon Biologics completes integration of biosimilars business in 70+ emerging markets

 05-July-2023

external_link-01
Biocon Biologics Ltd launches biosimilar HULIO in US

 05-July-2023

external_link-01
Biocon Biologics Ltd launches biosimilar HULIO in US

 05-July-2023

external_link-01
Biocon Biologics Receives EU Good Manufacturing Practice Certification

10-July-2022

external_link-01
Biocon Biologics’ antibody drug unit in Bengaluru gets EU GMP certificate

06-July-2022

external_link-01
Biocon Biologics receives EU GMP certification for its new biologics manufacturing facility in Bengaluru

 05-July-2022

external_link-01
Biocon Biologics expects big gains from integration of Viatris business, SII deal

 09-June-2022

external_link-01
Expect regulatory nods for deal with Serum and Viatris to come by H2: Kiran Mazumdar-Shaw, chairperson, Biocon and Biocon Biologics

04-May-2022

external_link-01
Biocon Biologics may close $3.34 billion Viatris deal in Q1

02-May-2022

external_link-01
Eyeing over 15% market share in US for insulin Glargine: Shreehas Tambe

30-April-2022

external_link-01
Biocon Biologics expects R&D expenses to hover between 10-15% in the next financial year

29-April-2022

external_link-01
Biocon Biologics acquires Viatris for $3.33 billion

01-Mar-2022

external_link-01
Biocon Biologics acquires Viatris’ biosimilars business in $3.3 bn deal

28-Feb-2022

external_link-01
R&D expenditure will rise in the coming quarters: Biocon Biologics MD

25-Jan-2022

external_link-01